Cholangiocarcinoma is an uncommon malignancy that increases with age. Cholangiocarcinoma has been linked to inflammatory bowel disease, and a relationship between inflammatory bowel disease, anti-tumour necrosis factor alpha antibody (Infliximab) and cholangiocarcinoma has been suggested. Although cholangiocarcinoma is usually associated with ulcerative colitis, recently more cases are being seen in association with Crohn's disease. The risk of cancer in patients treated with Infliximab has been discussed, and whether Infliximab is associated with an increased risk of cholangiocarcinoma is not clear. Cholangiocarcinoma is an uncommon malignancy and it is difficult to establish a clear correlation with Infliximab treatment. A large number of reports are needed to further address these issues.
year later. He was treated with Azathioprine along with Infliximab for a short period of time. An induction regimen of 3 single-dose infusions of 5 mg per kg of Infliximab at 0, 2, and 6 weeks was used. Patient slightly improved but 3 months later developed painless obstructive jaundice and was diagnosed with cholangiocarcinoma.
The introduction of Infliximab has offered new treatment options in patients with Crohn's disease and changed disease outcome [5] . The risk of cancer after anti-TNF therapy is controversial [6] [7] [8] . However, it is difficult to prove a link between exposure and tumour development in these patients, since they may already be predisposed to cancer as a consequence of their underlying disease [9] .
The correlation between Infliximab therapy and the development of cholangiocarcinoma in our patient was claimed. Liver function disorders were excluded before treatment. However, dimension at diagnosis suggested that the tumour was probably already present when Infliximab was administered. In this case, cholangiocarcinoma is likely a complication of Inflammatory Bowel Disease rather than of Infliximab infusion. It could be questioned whether immunosuppression might have increased the rate of tumour growth in our patient. Due to the liver toxicity of Infliximab and the risk of hepatic and biliary complications in Crohn's patients, liver function and imaging should always be carefully evaluated before Infliximab administration [10] . Cholangiocarcinoma is an uncommon but know extra-intestinal cancer complicating Inflammatory Bowel Disease [11] . Patients with Inflammatory Bowel Disease have a four-fold increased risk of developing cholangiocarcinoma, especially when they suffer from Ulcerative Colitis [12] . To our knowledge, only five studies in the literature reported an association between cholangiocarcinoma and Crohn's disease, with a total number of 9 cases (see Table 1) [13] [14] [15] [16] [17] . Most patients were female, young, and with a long duration of the disease before development of cholangiocarcinoma, with a severe prognosis and low survival. Tumour location was prevalently the hilum. Infliximab therapy was only recorded in one case, in association with Azathioprine and previous long course of Metronidazole, which safety is also controversial [17] .
The risk of cancer in patients treated with Infliximab has been discussed, and whether Infliximab is associated with an increased risk of cholangiocarcinoma is not clear. Possible correlation of Infliximab administration and cholangiocarcinoma deserves more accurate designed studies, large case series, than single case reports.
